Drug Profile
C 5889
Alternative Names: C-5889Latest Information Update: 18 Feb 2008
Price :
$50
*
At a glance
- Originator Merck & Co
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 11 Nov 2005 Phase-I clinical trials in Cancer in USA (unspecified route)